280CC, Scientist / Associate Scientist, Cancer Immunotherapy

Job Code 280CC

Description

Fate Therapeutics is currently seeking a skilled and motivated cell biologist to support the company’s Cancer Immunotherapy programs. The successful candidate will join a multidisciplinary team pursuing the development and characterization of next generation engineered T and CAR-T cells from gene edited induced pluripotent stem cells (iPSCs) for the development of off-the-shelf immunotherapies. The candidate must have good knowledge of cell biology with emphasis on T cell biology and immunology. The candidate will perform, optimize and analyze experiments involving the in vitro differentiation of iPSC towards the T lymphoid lineage. Primary responsibilities will include the derivation and characterization of novel platforms to generate functional subsets of T lymphocytes from iPSCs, including the planning and execution of functional assays and the support of downstream application groups. This position will require independent research as well as coordination with the molecular biology, cellular engineering and process development groups. This is a full-time position reporting to a Lead Scientist, Cancer Immunotherapy and is located at our corporate headquarters in San Diego, CA.

Download a PDF of the job description for more details:

View PDF

For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 280CC.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product candidate pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.